Literature DB >> 30390767

Diagnosis and Treatment of Ovarian Cancer.

Brian Orr1, Robert P Edwards2.   

Abstract

Epithelial ovarian cancer classically presents with vague persistent gastrointestinal, urologic, or nonacute abdominal/pelvic symptoms (bloating, early satiety, discomfort). Ultimately, a pelvic examination or imaging identifies an adnexal mass typically with accompanied advanced peritoneal dissemination. Management involves aggressive cytoreductive surgery in combination with platinum and taxane chemotherapy. Over the last 20 years, optimal resection and mode and timing of chemotherapy have evolved. The authors review the initial diagnosis and management and present the available data and recommendations to guide the decision tree of when to use neoadjuvant, intraperitoneal, HIPEC, dose-dense, and maintenance chemotherapy in the front-line treatment of epithelial ovarian cancer.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Dose-dense; HIPEC; Intraperitoneal; Neoadjuvant; Ovarian cancer

Mesh:

Substances:

Year:  2018        PMID: 30390767     DOI: 10.1016/j.hoc.2018.07.010

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  69 in total

1.  Long non-coding RNA LINC00504 regulates the Warburg effect in ovarian cancer through inhibition of miR-1244.

Authors:  Ya Liu; Xiaocui He; Yuli Chen; Dan Cao
Journal:  Mol Cell Biochem       Date:  2019-11-05       Impact factor: 3.396

Review 2.  Combinatorial therapy of immune checkpoint and cancer pathways provides a novel perspective on ovarian cancer treatment.

Authors:  Guyu Zhang; Chongdong Liu; Huiming Bai; Guangming Cao; Ran Cui; Zhengyu Zhang
Journal:  Oncol Lett       Date:  2019-01-08       Impact factor: 2.967

3.  Apparent diffusion coefficient histogram analysis for differentiating solid ovarian tumors.

Authors:  Renwei Liu; Ruifeng Li; Jinzhi Fang; Kan Deng; Cuimei Chen; Jianhua Li; Zhiqing Wu; Xiaoxu Zeng
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 4.  Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.

Authors:  Irina Larionova; Gulnara Tuguzbaeva; Anastasia Ponomaryova; Marina Stakheyeva; Nadezhda Cherdyntseva; Valentin Pavlov; Evgeniy Choinzonov; Julia Kzhyshkowska
Journal:  Front Oncol       Date:  2020-10-22       Impact factor: 6.244

Review 5.  Current update on malignant epithelial ovarian tumors.

Authors:  Sherif B Elsherif; Priya R Bhosale; Chandana Lall; Christine O Menias; Malak Itani; Kristina A Butler; Dhakshinamoorthy Ganeshan
Journal:  Abdom Radiol (NY)       Date:  2021-06-05

6.  Lassa-VSV chimeric virus targets and destroys human and mouse ovarian cancer by direct oncolytic action and by initiating an anti-tumor response.

Authors:  A N van den Pol; X Zhang; E Lima; M Pitruzzello; N Albayrak; A Alvero; J N Davis; G Mor
Journal:  Virology       Date:  2020-11-12       Impact factor: 3.616

7.  LAMA3 DNA methylation and transcriptome changes associated with chemotherapy resistance in ovarian cancer.

Authors:  Li-Yuan Feng; Yong-Zhi Huang; Wei Zhang; Li Li
Journal:  J Ovarian Res       Date:  2021-05-15       Impact factor: 4.234

8.  Role of sex hormones in modulating breast and ovarian cancer associated pain.

Authors:  Melissa C McHann; Henry L Blanton; Josée Guindon
Journal:  Mol Cell Endocrinol       Date:  2021-05-24       Impact factor: 4.369

9.  Factors impacting the time to ovarian cancer diagnosis based on classic symptom presentation in the United States.

Authors:  Sarah P Huepenbecker; Charlotte C Sun; Shuangshuang Fu; Hui Zhao; Kristin Primm; Sharon H Giordano; Larissa A Meyer
Journal:  Cancer       Date:  2021-08-04       Impact factor: 6.860

10.  Carbon Dioxide Pneumoperitoneum May Alter Ovarian Apoptosis: An Experimental Study.

Authors:  Suleyman Guven; Hidayet Sal; Emine Seda Guvendag Guven
Journal:  Gynecol Minim Invasive Ther       Date:  2021-04-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.